Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Is there a protective role of testosterone against high-grade prostate cancer? Incidence and severity of prostate cancer in 553 patients who underwent prostate biopsy: a prospective data register.
Yassin A, Salman M, Talib RA, Yassin DJ. Yassin A, et al. Aging Male. 2017 Jun;20(2):125-133. doi: 10.1080/13685538.2017.1298584. Epub 2017 Mar 10. Aging Male. 2017. PMID: 28282997
Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries.
Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Haider A, et al. J Urol. 2015 Jan;193(1):80-6. doi: 10.1016/j.juro.2014.06.071. Epub 2014 Jun 26. J Urol. 2015. PMID: 24980615 Clinical Trial.
Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes.
Haider A, Yassin A, Doros G, Saad F. Haider A, et al. Int J Endocrinol. 2014;2014:683515. doi: 10.1155/2014/683515. Epub 2014 Mar 11. Int J Endocrinol. 2014. PMID: 24738000 Free PMC article.
Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy.
Salman M, Yassin DJ, Shoukfeh H, Nettleship JE, Yassin A. Salman M, et al. Aging Male. 2017 Mar;20(1):45-48. doi: 10.1080/13685538.2016.1260107. Epub 2017 Jan 13. Aging Male. 2017. PMID: 28084147 Clinical Trial.
Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study).
Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH, Cuzin B, Moncada I, Martin-Morales A, Yassin A, Meuleman E, Eardley I, Dean JD, Shabsigh R. Buvat J, et al. J Sex Med. 2011 Jan;8(1):284-93. doi: 10.1111/j.1743-6109.2010.01956.x. J Sex Med. 2011. PMID: 20704642 Clinical Trial.
Endocrine aspects of male sexual dysfunctions.
Buvat J, Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, Schulman C, Tan HM, Torres LO, Yassin A, Zitzmann M. Buvat J, et al. J Sex Med. 2010 Apr;7(4 Pt 2):1627-56. doi: 10.1111/j.1743-6109.2010.01780.x. J Sex Med. 2010. PMID: 20388162
Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. van Ahlen H, et al. J Sex Med. 2005 Nov;2(6):856-64. doi: 10.1111/j.1743-6109.2005.00150.x. J Sex Med. 2005. PMID: 16422810 Clinical Trial.
Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study.
Haider A, Yassin A, Haider KS, Doros G, Saad F, Rosano GM. Haider A, et al. Vasc Health Risk Manag. 2016 Jun 14;12:251-61. doi: 10.2147/VHRM.S108947. eCollection 2016. Vasc Health Risk Manag. 2016. PMID: 27366080 Free PMC article. Clinical Trial.
33 results
Jump to page
Feedback